Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 11
Submit an article Journal homepage
53
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Rituximab Provides Durable Remission in a Patient with Refractory Aggressive Diffuse B-cell Lymphoma Failing Salvage Chemotherapy

Eric Robach Section of Hematology/Oncology, Department of Medicine, Medical College of Georgia, 1120 15th Street, BAA 5407, Augusta, GA 30912-3125, USA
,
Celalettin Ustun Section of Hematology/Oncology, Department of Medicine, Medical College of Georgia, 1120 15th Street, BAA 5407, Augusta, GA 30912-3125, USA
,
Andre Kallab Section of Hematology/Oncology, Department of Medicine, Medical College of Georgia, 1120 15th Street, BAA 5407, Augusta, GA 30912-3125, USA
,
Russel E. Burgess Section of Hematology/Oncology, Department of Medicine, Medical College of Georgia, 1120 15th Street, BAA 5407, Augusta, GA 30912-3125, USA
&
Anand P. Jillella Section of Hematology/Oncology, Department of Medicine, Medical College of Georgia, 1120 15th Street, BAA 5407, Augusta, GA 30912-3125, USA
Pages 2235-2236 | Published online: 01 Jul 2009

  • Cheson, B.D. (2002) "CHOP plus rituximab --balancing tacts and opinion". New England Journal of Medicine 346, 280-282.
  • Coiffier. B. (2001) "Diffuse large cell Iymphoma". Current Opinion in Oncology 13, 325-334.
  • Coiffier. B., Lepage. E., Briere, J., Herbrecht. R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. and Gisselbrecht, C. (2002) "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lyniphoma", New England Journal of Medicine 346, 235-242.
  • Wilson, W.H., Gutierrez, M., O'Conner, P., Frankel, S., Jaffe, E., Chabner, B.A. and Grossbard, M.L. (2002) "The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose adjusted EPOCH-R", Seminars in Oncology 29(Suppl. 2), 41-47.
  • Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M, Radford, I.A., Capdeville, R., Diehl, V. and Reyes, F. (1998) "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenler phase II study", Blood 92, 1927-1932.
  • Savage, D.G. and Staron, R. (2001) "Rituximab for bone lymphoma", Annals of Internal Medicine 134, 1156-1157.
  • Pan, D., Moskowitz, C.H., Zelenetz, A.D., Teruya-Feldstein, J. and Portlock, C.S. (2000) "Clinical outcomes of patients treated with retuximab for relapsed or refractory aggressive lymphoma in the post transplant setting". Blood 96, 405a, (abstr 1746).
  • The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) "A predictive model for aggressive non-Hodgkin's lymphoma", New England Journal of Medicine 329, 987-994.
  • Coiffier, B. (2002) "Rituximab in the Treatment of Diffuse Large B Cell Lymphomas", Seminars in Oncology 29, 30-35.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.